Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic renal anemia;~* hemodialysis 3 times weekly for \>=12 weeks before screening, and during screening/baseline period;~* receiving darbepoetin alfa maintenance therapy for \>=8 weeks before screening, and during screening/baseline period.~Exclusion Criteria:~* overt gastrointestinal bleeding within 8 weeks before screening or during screening/baseline period;~* transfusion of red blood cells within 8 weeks before screening or during screening/baseline period;~* active malignancy;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MIRCERA (Type: EXPERIMENTAL): Eligible participants with anemia in CKD who were on hemodialysis will receive methoxy polyethylene glycol-epoetin beta (MIRCERA \[RO0503821\]) IV once every month up to 52 weeks. The starting dose of MIRCERA which will be administered during the treatment period will depend on the dose of darbepoetin alfa administered during screening period i.e., 120, 200 and 360 mcg for weekly darbepoetin alfa doses of \<40, 40-80, and \>80 mcg, respectively.
- Darbepoetin Alfa (Type: ACTIVE_COMPARATOR): Eligible participants with anemia in CKD who were on hemodialysis will receive darbepoetin alfa (Aranesp) IV once every two weeks up to 26 weeks and darbepoetin alfa IV twice the dose than earlier, once every month from Week 27 up to Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).